STOCKHOLM, Sweden, May 10, 2005 (PRIMEZONE) -- Vitrolife:
-- Sales increased by 3 percent, to SEK 30.5 (29.5) million. Adjusted
for exchange-rate effects the increase was 6 percent.
-- Gross income amounted to SEK 20.6 (20.5) million and the gross
margin to 67 percent (69).
-- Operating income amounted to SEK 5.4 (5.4) million.
-- Net income for the Group was SEK 6.2 (6.1) million.
-- Earnings per share amounted to SEK 0.34 (0.33).
-- The equity/assets ratio increased to 83 percent (78).
-- Sale of the shares in Cellartis AB has led to a capital gain of
SEK 2.4 million.
-- Sales approval has been obtained for ICSI(tm) in the USA.
-- A patent concerning the use of alanyl-glutamine in media for
embryos and stem cells has been approved in the USA.
-- Powerful measures have been taken during the period with regard
to marketing, R&D and the expansion of production capacity.
May 10, 2005 Kungsbacka, Sweden
Magnus Nilsson CEO
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Cell therapy. The Fertility product area works with nutrient solutions (media) for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Cell therapy product area works with media to enable the use of stem cells for therapeutic purposes.
Vitrolife today has approximately 80 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there is a subsidiary in Denver, USA. The Vitrolife share is listed on the O-list of the Stockholm Stock Exchange.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=96735&fn=wkr0001.pdf